The treatment of active chronic B hepatitis using lamivudine

This randomized, placebo-controlled clinical study evaluated the efficacy of lamivudine in 44 Vietnamese patients with histologically documented chronic hepatitis B for one-year. The patients were randomly assigned to receive 100 mg of lamivudine (22 patients) orally once daily or placebo (22 patients). The patients underwent liver biopsies before entering the study and after completing the assigned treatment regimen. At the end of therapy, the percentage of serum HBVDNA negativation was higher in the lamivudine group (86.4%) than in the control group (22% P2 points of improvement versus placebo. Lamivudine is less side effects, safety, and favorable

To study the variation of histological activity indices in chronic B hepatitis patients treated by limivudine

44 patients of chronic B hepatitis are divided into two groups of 22 patients. The one is treated with lamivudine (Jefflix) 100 mg daily in 12 months continuously and the other with usual vitamin and liver tonics. Results showed in 72.7% patients of lamivudine group, the indices of histological activities were improved (through Knodell score), while in controlled group – 31.8% and over the half of this group these indices worsened. Thus, lamivudine has got good effect